Adze Biotechnology and King’s College London Announce Clinical Collaboration in hard-to-treat Breast Cancers
Adze Biotechnology, Inc., a pioneering preclinical-stage company developing systemically deliverable oncolytic immunotherapies, today announced a collaboration with King’s College London to support an investigator-initiated clinical trial evaluating ADZE1.











